Ultime notizie per Curis (NASDAQ:CRIS) Azioni

Curis

Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

Curis Inc

CRISPR THERAPEUTICS ORD

CRISPR Therapeutics AG

CRISM THERAPEUTICS CORP by CRISM THERAPEUTICS CORP

Crism Therapeutics Corp

CRIS

Curis 13G Filing Shows Thomas A. Satterfield, Jr. Reported A 8.05% Stake In The Co As Of October 30, 2024

HC Wainwright &amp; Co. analyst Edward White maintains Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) with a Buy and lowers the price target from $26 to $20.

News

Price Target

Analyst Ratings

HC Wainwright & Co. Maintains Buy on Curis, Lowers Price Target to $20

The unregistered warrants to be issued in the concurrent private placement will have an exercise price of $4.92 per share of common stock, will be exercisable immediately and will expire five years following the issuance date. The combined purchase price for one share of common stock and the associated unregistered warrant is $5.045.

Biotech

Health Care

Financing

Offerings

General

Curis Has Announced A Registered Direct Offering Of 2.39M Shares Priced At-The-Market And A Concurrent Private Placement Of Unregistered Warrants To Purchase Up To An Aggregate Of 2.398M Shares

HC Wainwright &amp; Co. analyst Edward White reiterates Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) with a Buy and maintains $26 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Curis, Maintains $26 Price Target

Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) reported quarterly losses of $(2.03) per share which missed the analyst consensus estimate of $(1.67) by 21.56 percent. This is a 17.81 percent increase over losses of $(2.47) per share from the same period last year. The company reported quarterly sales of $2.546 million which beat the analyst consensus estimate of $2.064 million by 23.37 percent. This is a 15.89 percent increase over sales of $2.197 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Curis Q2 2024 GAAP EPS $(2.03) Misses $(1.67) Estimate, Sales $2.546M Beat $2.064M Estimate

<h3>Gainers</h3>
<ul>
<li>Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) stock moved upwards by 34.0% to $0.82 during Monday's regular session. The company's market cap stands at $124.5 million. </li>
<li>Renovaro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENB#NASDAQ">RENB</a>) shares increased by 32.51% to $1.71. The market value of their outstanding shares is at $252.1 million. </li>
<li>Champions Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSBR#NASDAQ">CSBR</a>) shares increased by 22.82% to $5.65. The company's market cap stands at $76.8 million. </li>
<li>Nanoviricides (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NNVC#AMEX">NNVC</a>) stock rose 22.02% to $3.26. The market value of their outstanding shares is at $38.4 million. </li>
<li>Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) stock moved upwards by 20.13% to $38.0. The market value of their outstanding shares is at $268.5 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) stock moved upwards by 18.63% to $1.3. The company's market cap stands at $8.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) stock fell 35.6% to $0.36 during Monday's regular session. The company's market cap stands at $6.8 million. </li>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) stock fell 31.74% to $3.55. The company's market cap stands at $2.7 million. </li>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) stock decreased by 27.83% to $3.65. The company's market cap stands at $1.1 million. </li>
<li>Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) stock fell 19.58% to $7.11. The company's market cap stands at $41.9 million. </li>
<li>Skye Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYE#NASDAQ">SKYE</a>) stock fell 15.0% to $9.3. The market value of their outstanding shares is at $261.0 million. </li>
<li>Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) shares decreased by 14.62% to $15.52. The company's market cap stands at $2.2 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CNSP

CSBR

MCRB

NNVC

NVAX

RENB

RNAZ

SBFM

SKYE

SMLR

THAR

12 Health Care Stocks Moving In Monday's Intraday Session

Truist Securities analyst Robyn Karnauskas maintains Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) with a Buy and maintains $26 price target.

Truist Securities Maintains Buy on Curis, Maintains $26 Price Target

Cantor Fitzgerald analyst Li Watsek reiterates Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) with a Overweight.

Cantor Fitzgerald Reiterates Overweight on Curis

Data update expands AML dataset from 5 to 30 patients
LEXINGTON, Mass., May 14, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced updated data from the ongoing TakeAim Leukemia study (CA-4948-102) in relapsed/refractory (R/R) AML to be presented at the ASCO and EHA conferences.
This update includes data for 25 new patients in the FLT3 mutation (FLT3m) and U2AF1/SF3B1 Splicing Factor mutation (SFm) cohorts who had received fewer than 3 lines of prior therapy and were treated with emavusertib as monotherapy at the Recommended Phase 2 Dose (RP2D) of 300 mg BID.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">
Prior
Data
</td>
<td colspan="2" rowspan="1">New Data&#x2A;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Total</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">FLT3m AML</td>
<td colspan="2" rowspan="1">3</td>
<td colspan="1" rowspan="1">9</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">12</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">SFm AML</td>
<td colspan="2" rowspan="1">3</td>
<td colspan="1" rowspan="1">17</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">20</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">adjustment for patients with dual mutation&#x2A;&#x2A;</td>
<td colspan="2" rowspan="1">(1)</td>
<td colspan="1" rowspan="1">(1)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">(2)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="2" rowspan="1">5</td>
<td colspan="1" rowspan="1">25</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">30</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
</tbody>
</table>
</figure>
&#x2A;&nbsp; data cut-off as of February 26, 2024 &#x2A;&#x2A;&nbsp; 2 patients had both FLT3m and SFm (dual mutation) &nbsp; &nbsp; 1 patient in the initial group of 5 patients; 1 patient in the new group of 25 additional patients

Curis To Present Updated Data From TakeAim Leukemia Study  At The ASCO And EHA Conferences

Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) reported quarterly losses of $(2.05) per share which beat the analyst consensus estimate of $(2.12) by 3.3 percent. This is a 14.58 percent increase over losses of $(2.40) per share from the same period last year. The company reported quarterly sales of $2.09 million which missed the analyst consensus estimate of $2.40 million by 13.08 percent. This is a 9.19 percent decrease over sales of $2.30 million the same period last year.

Curis Q1 EPS $(2.05) Beats $(2.12) Estimate, Sales $2.09M Miss $2.40M Estimate

As of April 12, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#39;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#39;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi"> RSI is above 70</a>, according to <a href="https://pro.benzinga.com/"> Benzinga Pro</a>.
Here&rsquo;s the latest list of major overbought players in this sector.
<h3>OncoCyte Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocx#NASDAQ">OCX</a>)</h3>
<ul>
<li>On April 11, Oncocyte announced a $15.8 million private placement of securities priced at-the-market under Nasdaq rules. The company&rsquo;s stock gained around 4% over the past five days and has a <a href="https://www.benzinga.com/quote/OCX">52-week high of $6.80 </a>.</li>
<li>RSI Value: 73.87</li>
<li>OCX Price Action: Shares of OncoCyte rose 1.2% to close at $2.9650 on Thursday.</li>
</ul>
<h3>Curis, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cris#NASDAQ">CRIS</a>)</h3>
<ul>
<li>On April 5, Curis reported inducement grants under NASDAQ Listing Rule 5635(c)(4). The company&rsquo;s stock gained around 59% over the past month and <a href="https://www.benzinga.com/quote/CRIS"> has a 52-week high </a> of $17.49.</li>
<li>RSI Value: 75.26</li>
<li>CRIS Price Action: Shares of Curis gained 4.1% to close at $15.90 on Thursday.</li>
</ul>
<h3>Revolution Medicines, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rvmd#NASDAQ">RVMD</a>)</h3>
<ul>
<li>On April 9, the company announced the publication of a research paper on RMC-6236 in Cancer Discovery. The company&rsquo;s stock gained around 25% over the past five days and has a <a href="https://www.benzinga.com/quote/RVMD"> 52-week high </a> of $38.73.</li>
<li>RSI Value: 72.27</li>
<li>RVMD Price Action: Shares of Revolution Medicines gained 2.5% to close at $37.41 on Thursday.</li>
</ul>
&nbsp;
Read More: <a href="https://www.benzinga.com/news/earnings/24/04/38215617/fear-greed-index-moves-to-greed-zone-following-ppi-data-nasdaq-record-sharp-gains"> Fear &amp; Greed Index Moves To &#39;Greed&#39; Zone Following PPI Data; Nasdaq record Sharp Gains </a>

Penny Stocks

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

RVMD

Top 3 Health Care Stocks That May Collapse In Q2

<h3>Gainers</h3>
<ul>
<li>Candel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) shares moved upwards by 64.3% to $2.76 during Thursday's regular session. The market value of their outstanding shares is at $80.9 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) shares increased by 61.38% to $2.1. The market value of their outstanding shares is at $5.0 million. </li>
<li>Eiger BioPharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EIGR#NASDAQ">EIGR</a>) shares moved upwards by 38.18% to $2.28. The company's market cap stands at $3.3 million. </li>
<li>Macrogenics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) stock rose 32.55% to $18.12. The company's market cap stands at $1.1 billion. </li>
<li>Barinthus Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRNS#NASDAQ">BRNS</a>) shares increased by 29.55% to $3.77. The company's market cap stands at $146.7 million. </li>
<li>Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) shares moved upwards by 24.62% to $16.7. The market value of their outstanding shares is at $98.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>eFFECTOR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFTR#NASDAQ">EFTR</a>) stock declined by 80.2% to $3.25 during Thursday's regular session. The company's market cap stands at $11.9 million. </li>
<li>Achilles Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHL#NASDAQ">ACHL</a>) stock decreased by 24.17% to $0.91. The market value of their outstanding shares is at $37.1 million. As per the press release, Q4 earnings came out today. </li>
<li>Inotiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOTV#NASDAQ">NOTV</a>) shares fell 16.81% to $7.87. The company's market cap stands at $202.9 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock declined by 14.55% to $2.35. The company's market cap stands at $8.5 million. </li>
<li>Kintara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTRA#NASDAQ">KTRA</a>) shares declined by 13.48% to $0.14. The market value of their outstanding shares is at $5.5 million. </li>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) stock declined by 12.85% to $2.51. The market value of their outstanding shares is at $48.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACHL

BRNS

CADL

CTCX

EFTR

EIGR

Kintara Therapeutics, Inc. - Common Stock

KTRA

MGNX

NOTV

TCBP

12 Health Care Stocks Moving In Thursday's Intraday Session

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>Telsey Advisory Group raised the price target for Ralph Lauren Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rl#NYSE">RL</a>) from $165 to $195. Telsey Advisory Group analyst Dana Telsey maintained an Outperform rating. Ralph Lauren shares jumped 16.8% to close at $171.85 on Thursday. <a href="https://www.benzinga.com/quote/RL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HSBC cut Bunge Global SA (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bg#NYSE">BG</a>) price target from $122 to $105. HSBC analyst Wesley Brooks upgraded the stock from Hold to Buy. Bunge Global shares fell 1.7% to close at $86.50 on Thursday. <a href="https://www.benzinga.com/quote/BG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies boosted the price target for Inotiv, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/notv#NASDAQ">NOTV</a>) from $3 to $11.5. Jefferies analyst David Windley upgraded the stock from Hold to Buy. Inotiv shares gained 16.8% to close at $4.30 on Thursday. <a href="https://www.benzinga.com/quote/NOTV/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wells Fargo cut Everest Group, Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eg#NASDAQ">EG</a>) price target from $484 to $402. Wells Fargo analyst Elyse Greenspan downgraded the stock from Overweight to Equal-Weight. Everest Group shares fell 7.7% to close at $354.56 on Thursday. <a href="https://www.benzinga.com/quote/EG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity boosted the price target for Spectrum Brands Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/spb#NYSE">SPB</a>) from $83 to $86. Canaccord Genuity analyst Brian McNamara downgraded the stock from Buy to Hold. Spectrum Brands shares rose 7.7% to close at $86.10 on Thursday. <a href="https://www.benzinga.com/quote/SPB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup cut the price target for Albemarle Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/alb#NYSE">ALB</a>) from $175 to $120. Citigroup analyst Patrick Cunningham downgraded the stock from Buy to Neutral. Albemarle shares fell 0.6% to close at $114.33 on Thursday. <a href="https://www.benzinga.com/quote/ALB/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham increased CyberArk Software Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cybr#NASDAQ">CYBR</a>) price target from $245 to $310. Needham analyst Alex Henderson maintained a Buy rating. CyberArk Software shares gained 7.6% to close at $261.60 on Thursday. <a href="https://www.benzinga.com/quote/CYBR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler boosted Paylocity Holding Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pcty#NASDAQ">PCTY</a>) price target from $207 to $210. Piper Sandler analyst Arvind Ramnani maintained an Overweight rating. Paylocity Holding shares gained 2.1% to close at $171.91 on Thursday. <a href="https://www.benzinga.com/quote/PCTY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. slashed Curis, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cris#NASDAQ">CRIS</a>) price target from $51 to $26. HC Wainwright &amp; Co. analyst Edward White maintained a Buy rating. Curis shares rose 13.4% to close at $10.65 on Thursday. <a href="https://www.benzinga.com/quote/CRIS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Citigroup boosted Liberty Global Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lbtya#NASDAQ">LBTYA</a>) price target from $20 to $24. Citigroup analyst Nayab Amjad upgraded the stock from Neutral to Buy. Liberty Global shares fell 1.1% to close at $19.06 on Thursday. <a href="https://www.benzinga.com/quote/LBTYA/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
&nbsp;
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/02/37030079/dbv-technologies-and-2-other-stocks-under-2-insiders-are-buying"> DBV Technologies And 2 Other Stocks Under $2 Insiders Are Buying </a>

CYBR

LBTYA

PCTY

CyberArk Software To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Friday

HC Wainwright &amp; Co. analyst Edward White maintains Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) with a Buy and lowers the price target from $51 to $26.

HC Wainwright & Co. Maintains Buy on Curis, Lowers Price Target to $26

Curis Said May Offer, Sell Shares Of Common Stock From Time To Time In One Or More Offerings Of Up To $300M In Aggregate Offering Price

Guidance

As Of December 31, 2023, Curis's Cash, Cash Equivalents And Investments Totaled $56.3M. Curis Expects Its Existing Cash, Cash Equivalents And Investments Should Enable Its Planned Operations Into 2025

Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) reported quarterly losses of $(2.03) per share which beat the analyst consensus estimate of $(2.11) by 3.79 percent. This is a 13.62 percent increase over losses of $(2.35) per share from the same period last year. The company reported quarterly sales of $2.70 million which missed the analyst consensus estimate of $3.02 million by 10.73 percent. This is a 6.62 percent decrease over sales of $2.89 million the same period last year.

Curis Q4 EPS $(2.03) Beats $(2.11) Estimate, Sales $2.70M Miss $3.02M Estimate

Curis Q2 2024 Earnings Preview

Curis GAAP EPS of -$2.03 misses by $0.35, revenue of $2.5M beats by $0.44M

Curis, Inc. (CRIS) Q2 2024 Earnings Call Transcript

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Curis (CRIS – Research Report). The company's sha...

Truist Financial Reaffirms Their Buy Rating on Curis (CRIS)

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Curis (CRIS – Research Report) today. The company's shares closed yesterda...

Truist Financial Sticks to Its Buy Rating for Curis (CRIS)

H.C. Wainwright analyst Edward White maintained a Buy rating on Curis (CRIS – Research Report) today and set a price target of $26.00. Edward White...

Buy Rating Affirmed for Curis on Emavusertib's Promising Clinical Data and Market Potential

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Curis (CRIS – Research Report), Scholar Rock Holding...

Analysts Offer Insights on Healthcare Companies: Curis (CRIS), Scholar Rock Holding (SRRK) and Travere Therapeutics (TVTX)

Curis looks to raise $12.1M in private placement

H.C. Wainwright lowered the firm's price target on Curis (CRIS) to $20 from $26 and keeps a Buy rating on the shares. The firm cites dilution from ...

Curis price target lowered to $20 from $26 at H.C. Wainwright

H.C. Wainwright analyst Edward White reiterated a Buy rating on Curis (CRIS – Research Report) today and set a price target of $20.00. Edward White...

Comments

Curis

Notizie

Ultime notizie per Curis (NASDAQ:CRIS) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO